HIV control through treatment durably prevents heterosexual transmission of virus

NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners

2015-07-20

(Press-News.org) Antiretroviral treatment that consistently suppresses HIV is highly effective at preventing sexual transmission of the virus in heterosexual couples where one person is HIV-infected and the other is not, investigators report today at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention (IAS 2015) in Vancouver, Canada. The finding comes from the decade-long HPTN 052 clinical trial funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIH-funded HIV Prevention Trials Network (HPTN).

In 2011, the HPTN 052 study investigators reported a breakthrough: Starting HIV treatment early, when the immune system is relatively healthy, reduced the risk of sexually transmitting the virus to an uninfected partner by 96 percent over 18 months. Based on additional data gathered since 2011, today's finding unequivocally demonstrates the enduring power of HIV-controlling antiretroviral therapy to greatly reduce sexual transmission of the virus.

"The study now makes crystal clear that when an HIV-infected person takes antiretroviral therapy that keeps the virus suppressed, the treatment is highly effective at preventing sexual transmission of HIV to an uninfected heterosexual partner," said NIAID Director Anthony S. Fauci, M.D. "For heterosexuals who can achieve and maintain viral suppression, the risk to their partners is exceedingly low."

The HPTN 052 trial was designed to evaluate whether antiretroviral therapy reduces sexual transmission of HIV. Beginning in April 2005, the study enrolled 1,763 heterosexual couples ages 18 or older in Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand, the United States and Zimbabwe. Each couple included one partner with HIV infection and one without. Infected participants were assigned at random either to start antiretroviral therapy right away, while their immune system was relatively healthy, or to delay starting treatment until their immune system weakened or they developed an AIDS-defining illness, consistent with World Health Organization guidelines at the time. All participants received condoms and counseling on how to protect their partners from sexual transmission of HIV.

Once the investigators reported their landmark data in 2011, all infected study participants were offered the opportunity to begin antiretroviral therapy right away, and the trial continued for another four years, concluding this spring. At the end of the study, 1,171 couples remained in the trial.

Investigators report today that starting antiretroviral therapy early reduced HIV transmission by 93 percent over the course of the study. Only eight cases of HIV transmission occurred in uninfected partners of HIV-infected participants who received antiretroviral therapy. Four of these infections were diagnosed shortly after the start of treatment. In these cases, the virus most likely was transmitted just before antiretroviral therapy began or right after it commenced, before treatment had fully suppressed HIV replication. The other four infections occurred in study participants for whom treatment no longer was working and the virus was replicating. Treatment failure may have occurred because HIV-infected participants did not take their antiretroviral drugs as prescribed or had an HIV strain that was resistant to one or more of the drugs in their treatment regimen.

The lack of sexual transmission of HIV by virally suppressed individuals in this large study provides robust evidence that antiretroviral therapy started at any time in the course of infection can prevent heterosexual HIV transmission if viral suppression is achieved and maintained, the investigators note.

"Throughout our decade-long study with more than 1,600 heterosexual couples, we did not observe HIV transmission when the HIV-infected partner's virus was stably suppressed by antiretroviral therapy," said Myron Cohen, M.D., the study's principal investigator. Dr. Cohen is Associate Vice Chancellor for Global Health at the University of North Carolina at Chapel Hill and director of the university's Institute for Global Health and Infectious Diseases. "These findings illustrate that treatment is an incredibly powerful tool for HIV prevention."

HPTN 052 investigators also are reporting findings today about relationships between viral load, viral suppression, treatment failure and drug resistance. The researchers found that having a relatively high level of HIV in the blood at the start of therapy was associated with a longer time to viral suppression, which, in turn, was associated with both the occurrence of treatment failure and a shorter time to treatment failure. Thus, having a relatively high viral load at the start of treatment could increase the risk for HIV transmission, the scientists suggest.

In addition, the investigators found that among the HPTN 052 participants who started antiretroviral therapy early but failed treatment before May 2011, those who had a higher viral load when they joined the study were likely to develop resistance to their antiretroviral drugs. Additional analysis is needed to clarify this association, according to the investigators.

INFORMATION:

The HPTN conducted the trial with funding from NIAID, the National Institute on Drug Abuse and the National Institute of Mental Health, all part of NIH, through grant number 5-UM1-AI068619. Additional support was provided by the NIH-funded AIDS Clinical Trials Group.

For more information about the HPTN 052 trial, please see Questions and Answers: The HPTN 052 Study: Preventing Sexual Transmission of HIV with Anti-HIV Drugs. Information is also available in ClinicalTrials.gov under study identifier NCT00074581.

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIH...Turning Discovery Into Health® References

M Cohen, et al. Final results of the HPTN 052 randomized controlled trial: antiretroviral therapy prevents HIV transmission. Program number MOAC0106LB, Track C.

SH Eshleman, et al. Treatment as prevention: characterization of partner infections in the HIV Prevention Trials Network 052 trial. Program number MOAC0106LB, Track C.

J Fogel, et al. Identification of factors associated with viral suppression and treatment failure when antiretroviral therapy is used for HIV prevention: results from the HIV Prevention Trials Network (HPTN 052) trial. Program number MOPEC417, Track C.

D Sabin, et al. Analysis of HIV drug resistance in adults receiving early antiretroviral treatment for HIV prevention: results from the HIV Prevention Trials Network (HPTN 052) trial. Program number TUPEB285, Track B.

ELSE PRESS RELEASES FROM THIS DATE:

Novel glycoengineering technology gives qualitative leap for biologics drug research

2015-07-20

Researchers from the University of Copenhagen have discovered a way of improving biotech drugs. Better, cheaper and more effective drugs to combat cancer, arthritis and many other disorders. This is the result of a ground-breaking new technique developed by a group of researchers from the Faculty of Health and Medical Sciences at the University of Copenhagen. The method can improve a large number of so-called glycoprotein-based pharmaceuticals used to treat a variety of diseases. The technique has recently been described in one of the world's most distinguished scientific ...

Adolescent friendship study confirms 'birds of a feather flock together -- stay together'

2015-07-20

No one likes to lose a friend, especially adolescents. But why do friendships end? Researchers in the Charles E. Schmidt College of Science at Florida Atlantic University sought to answer this question with a study examining whether adolescent friendships end because of undesirable characteristics of friends, because of differences between friends, or both. Findings from this long-term longitudinal study of 410 adolescents involved in 573 friendships are published in the current issue of Psychological Science. Adolescent friendships are fleeting. The majority dissolve ...

The chemistry of wine (video)

2015-07-20

WASHINGTON, July 20, 2015 -- If you're stumped in the wine aisle of the store, then you're not alone. Every bottle has unique nuances of taste and smell. How can something made of grapes smell buttery or taste like grass? Learn about the complex chemistry behind wine and then impress your friends at your next party thanks to Reactions. Check out our wine chemistry primer here: http://youtu.be/_UaS743_aEs. Subscribe to the series at http://bit.ly/ACSReactions, and follow us on Twitter @ACSreactions to be the first to see our latest videos. INFORMATION: The American ...

Life-saving breast cancer drugs going untaken in Appalachia

2015-07-20

Nearly a third of breast cancer survivors in Appalachia are not taking the critical, potentially life-saving follow-up treatment - despite having insurance that would pay for it, a troubling new study has found. Researchers cross-examined cancer registries with Medicare claims data and determined that of 428 women, approximately 30 percent failed to follow through with their prescribed adjuvant hormone therapy, a treatment to prevent the cancer's recurrence. "Almost a third of the prescriptions for adjuvant hormone therapy were not filled, which is much, much higher ...

Georgia State study finds state regulations linked to late cancer diagnoses

2015-07-20

ATLANTA--States' regulations of health insurance and practitioners significantly influence when patients receive colorectal or breast cancer diagnoses, especially among people younger than the Medicare-eligible age of 65, according to a new study by researchers at Georgia State University's School of Public Health and the University of North Carolina at Chapel Hill. The study suggests that where people live is a strong predictor of whether they will receive potentially life-saving cancer screenings. Dr. Lee Rivers Mobley, associate professor of spatial science and health ...

Ocean acidification may cause dramatic changes to phytoplankton

2015-07-20

Oceans have absorbed up to 30 percent of human-made carbon dioxide around the world, storing dissolved carbon for hundreds of years. As the uptake of carbon dioxide has increased in the last century, so has the acidity of oceans worldwide. Since pre-industrial times, the pH of the oceans has dropped from an average of 8.2 to 8.1 today. Projections of climate change estimate that by the year 2100, this number will drop further, to around 7.8 -- significantly lower than any levels seen in open ocean marine communities today. Now a team of researchers from MIT, the University ...

Marine travellers best able to adapt to warming waters

2015-07-20

Marine species that already roam far and wide throughout our oceans are extending their territories further and faster in response to climate change, according to new research involving the University of Southampton and an international team of biodiversity experts. The study found that while species that have large ranges are able to make their way to cooler waters, small-ranging species are in increased jeopardy as our planet's oceans continue to warm. "Our findings indicate that animals which already have wide-latitudinal ranges, habitat generalists, and species with ...

Yale researchers beat untreatable eczema with arthritis drug

2015-07-20

New Haven, Conn. -- Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug recently shown to reverse two other disfiguring skin conditions, vitiligo and alopecia areata. The study is evidence of a potential new era in eczema treatment, they report. The research findings are published early online in the Journal of the American Academy of Dermatology. Eczema (atopic dermatitis) is a chronic condition that causes severe itching and leaves the skin red and thickened. It can adversely affect ...

Warming slow-down not the end of climate change, study shows

2015-07-20

A slow-down in global warming is not a sign that climate change is ending, but a natural blip in an otherwise long-term upwards trend, research shows. In a detailed study of more than 200 years' worth of temperature data, results backed previous findings that short-term pauses in climate change are simply the result of natural variation. The findings support the likelihood that a current hiatus in the world's year-on-year temperature increases - which have stalled since 1998 - is temporary. Scientists from the University of Edinburgh analysed real-world historic ...

How neurons remember

2015-07-20

Research findings obtained over the past decades increasingly indicate that stored memories are coded as permanent changes of neuronal communciation and the strength of neuronalinterconnections. The learning process evokes a specific pattern of electrical activity in these cells, which influences the response behavior to incoming signals, the expression of genes and the cellular morphology beyond the learning process itself. "You might say that these changes define the cellular correlate of the memory engram" says Friedrich Johenning, researcher at the Neuroscience Research ...

LAST 30 PRESS RELEASES:

Novel supernova observations grant astronomers a peek into the cosmic past

Association of severe maternal morbidity with subsequent birth

Herodotus' theory on Armenian origins debunked by first whole-genome study

Women who suffer pregnancy complications have fewer children

Home testing kits and coordinated outreach substantially improve colorectal cancer screening rates

COVID-19 vaccine reactogenicity among young children

Generalizability of clinical trials of novel weight loss medications to the US adult population

Wildfire smoke exposure and incident dementia

Health co-benefits of China's carbon neutrality policies highlighted in new review

Key brain circuit for female sexual rejection uncovered

Electrical nerve stimulation eases long COVID pain and fatigue

ASTRO issues update to clinical guideline on radiation therapy for rectal cancer

Mount Sinai opens the Hamilton and Amabel James Center for Artificial Intelligence and Human Health to transform health care by spearheading the AI revolution